Somatostatin-based radioligands were shown to have sensitive imaging properties for neuroendocrine tumours and their metastases. 
[
nat Co]DOTA-TOC was assessed using autoradiographic methods on membranes transfected with human somatostatin receptor subtypes. These studies revealed that [ 57 Co]DOTATOC is an sst2-specific radiopeptide presenting the highest affinity ever found for the sst2 receptor subtype. The rate of internalisation into the AR4-2J cell line also was the highest found for any somatostatin-based radiopeptide. Biodistribution studies, performed in nude mice bearing the AR4-2J tumour or a transfected HEK-sst2 cell-based tumour, showed high and specific uptake in the tumour and in other sst receptor-expressing tissues reflecting the high receptor binding affinity and the high rate of internalisation. The pharmacologic differences between [ 57 Co]DOTATOC and [ 67 Ga]DOTA-TOC were discussed in terms of the structural parameters found for the chelate models Co II (DOTA) 2- and Ga
III

Introduction
The use of radionuclides in medical fields such as molecular imaging and targeted radionuclide therapy is in rapid expansion [1, 2] . Radiolabeled bioactive peptides are currently being employed in tumour targeting using both Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) [3] [4] [5] [6] [7] [8] [9] . PET is an imaging modality with the advantage of high spatial resolution, high sensitivity, and the potential of quantification. For these reasons it is nowadays considered one of the most powerful tools for molecular imaging. Bioactive peptides labelled with metallic particle-emitting isotopes, such as 90 Y III or 177 Lu III , allow peptide receptor-mediated radionuclide therapy (PRMRT) [10] . The first regulatory peptides developed for radiopharmaceutical applications have been somatostatin analogues, which are being employed in the diagnosis of somatostatin receptor-positive tumours when modified with the chelator DTPA (diethylenetriaminepentaacetic acid) and labelled with the γ-emitter 111 In [11] . Somatostatin is a tetradecapeptide produced by neuroendocrine, inflammatory and immune cells and is thought to be an important physiological regulator of numerous functions. Its action is mediated by five receptor subtypes (sst1-sst5), which belong to the G-protein coupled receptor family. All subtype receptors have been found to be overexpressed to some degree in different tumours, often concomitantly on the same cell [12] . By far most important is the overexpression of receptor subtype 2. It is therefore 2 conceivable to search for somatostatin analogues with improved affinity to sst2.
We have developed a DOTA (DOTA = 1,4,7,10-tetraazacyclododecane-N,N´,N´´,N´´´-tetraacetic acid)-derivatised somatostatin analogue, [DOTA 0 ,Tyr 3 ]-octreotide (DOTATOC, Figure 1) , [13] which has been successfully labelled with radiometals and proven to be useful in different areas of diagnostic and therapeutic nuclear oncology [14] . In particular the 68 Ga III -labelled peptide is currently being used in several European centres, affording very sensitive images of a variety of human tumours and showing an improved diagnostic accuracy, superior to other radiological imaging modalities such as [
111 In]DOTATOC [15] .
The 68 Ga-DOTATOC shows approximately 5-fold higher binding affinity to sst2 than [ 111 In/ 90 Y]DOTATOC ; in addition, it shows a higher rate of internalisation into sst2-expressing tumour cells, an approximately 2.5-fold higher tumour uptake and a significantly lower kidney uptake in animals and patients. We have previously shown that this difference in the biological behaviour of metallopeptides may be attributed to structural differences within the chelate moiety [13, 16] .
((Insert Figure 1 here)) (DOTA-D-PheNH 2 ) has eight-fold coordination including the amide carboxy oxygen with a somewhat distorted squareantiprismatic geometry. Distant from the pharmacophore of the molecule, this structural difference within the metal chelate leads to a five times higher receptor affinity and probably is also responsible for the mentioned improved biodistribution of the radiogallium-labelled compound. This superiority could also be confirmed clinically using [
68 Ga]DOTATOC in PET [17] and [ 67 Ga]DOTATOC in SPECT [13, 18] . This finding prompted us to exploit such structural features when using another positron-emitting metal, namely 55 Co II (t 1/2 17.5 h, β + (77%), EC (23%)). While the structures of the Ga III -and Co II -labelled peptides are expected to be similar, the use of the longer-lived cyclotronproduced 55 Co II as PET radiometal could allow imaging at later time points when target-to-background ratios are higher. In the literature there are reports of the use of 55 Co II as a PET radiometal in medical fields that range from cerebrovascular diseases [19] [20] [21] to studies of human lymphocyte distribution [22] and [ 55 Co]EDTA-based quantitative imaging of the kidneys [23] . In the present work we used 57 performed with the aim of potentially understanding the differences and similarities in the biological behaviour of the different radiometal-labelled peptides.
Results and Discussion
Synthesis, labelling and stability: The preparation of DOTATOC involves the coupling of the monoreactive DOTA(tBu) 3 -prochelator to the solid phase-assembled, side chain-protected peptide, as described in Ginj et al [24] . The model DOTA-peptide, DOTA-D-PheNH 2 , was synthesised in a similar way. DOTATOC was labelled with 57 Co II 59 Co NMR signal in a wide spectral window in aqueous solution. This is consistent with a +2 oxidation state. In an octahedral environment, divalent cobalt may be found in two different electronic states: a low spin t 2g 6 e g 1 state with one unpaired electron (S=1/2) and a high spin state t 2g 5 e g 2 with three unpaired electrons (S=3/2). The colour of the chelate is consistent with a high spin octahedral species, typically pale red or purple. Another strong indication for the high spin assignment comes from the X-ray structure. Low spin octahedral Co II complexes undergo Jahn-Teller distortion. In Co-DOTAH 2 the equatorial Co-N bond length (2.171 Ǻ) differs very little from the axial (2.203 Ǻ). This is contrary to the Jahn-Teller distorted Cu-DOTA (Cu-N eq = 2.107 Ǻ; Cu-N ax = 2.318 Ǻ).
Temperature-dependent 1 H NMR studies of Co-DOTA and Co-DOTA-D-PheNH 2 , in a large spectral window, revealed that the number of signals and their width can vary significantly, reflecting a combination of paramagnetic shift and exchange effects, consistent with a high spin state for the Co II ion. Our results demonstrate that dioxygen does not oxidise these polyamine polycarboxylate cobalt chelates despite the fact that the experiments were carried out in aerated solutions. This is in accordance with earlier reports that tertiary amine ligands stabilise low valent transition metal ions, in particular the Co II ion [25, 26] . [27] in this respect it is important to evaluate the kinetic stability of radiometal-labelled peptides under physiological conditions. For this purpose we measured the rate of 57 Co II transfer from [ 57 Co]DOTATOC in human blood serum. [28] The approximate transfer half-life is 800 h, which compares toT 1/2 =1250 h of [ 67 Ga]DOTATOC [13] .
Receptor binding assays III -DOTATOC has a fourfold lower sst2-affinity than SS28. Co II -DOTATOC shows the highest sst2 affinity of any somatostatin-based metallopeptide found so far. [12] Additionally, Co II -DOTATOC shows also higher affinity to sst4 than the other two metallopeptides but a distinctly lower sst5 affinity. >10000 (5) 2.0±0.7 (5)
>10000 (6) 2.5±0.5
613±140 (7) >1000 (6) 73±21 (6) [a] data from Reubi et al. [12] Internalisation and efflux
The specific internalisation of [ 57 Co]DOTATOC was evaluated using AR4-2J rat pancreatic tumour cells which exclusively express sst2. The radiometal-labelled peptide showed a time-dependent uptake with a very high specific internalisation rate, as shown in Figure 3 (scale of left y-axis and lower x-axis).
((Insert Figure 3 here)) 
After 6 h [
57 Co]DOTATOC showed almost 50% specific internalisation in 1 million cells, constituting the highest internalisation rate ever found for a somatostatin derivative. In the same cell line [
67 Ga]DOTATOC showed an uptake of 16.5±1% at 4 h p.i. [29] ; [ 57 Co]DOTATOC internalised about 30% at 4 h p.i. whereas [
111 In]DOTATOC internalised 11.5±0.7% of the total amount of radiopeptide added to 1 million cells. In order to evaluate the retention of the radiometal-peptide in the tumour cells, externalisation experiments were performed also in AR4-2J tumour cells. Cells were pre-loaded with [ 57 Co]DOTATOC for 2 h at 37°C. To remove the receptor-bound radiometal-peptide an acid
wash was carried out twice with a 0.1 M glycine buffer pH 2.8, 10 min, on ice. Afterwards, externalisation of [ 57 Co]DOTATOC was monitored at 30, 60, 120 and 240 min at 37°C, as shown in Figure 3 (scale of right y-axis). The externalisation results also showed a time dependence: the radiometal-labelled peptide presented circa 40% efflux from the cells within 4 h.
Biodistribution in tumour-bearing mice
For comparative reasons pharmacokinetic studies were performed in two mouse models (nude mice bearing the AR4-2J or HEK-sst2 tumour [30, 31] . The results are given in Tables 2 and 3 Less than 0.15% IA/g remained in blood after 4 h. The clearance from all somatostatin receptor-negative tissues including the kidneys is also fast. Unexpectedly, also the tumour uptake in the AR4-2J tumour decreased between 4 h and 24 h by >90%. This was never observed before in any somatostatin-based radiopeptide which usually show biological half-lives of ≥24 h in tumours of this tumour model [30] . The highest tissue activity was found in the kidneys, which demonstrates the renal excretion of the radiopharmaceutical. At all time points the uptake in other organs was considerably lower except for the stomach which has been known for its presence of somatostatin receptors. Some uptake could be seen in the pancreas and the adrenals as well, which was expected since these two organs express somatostatin receptors. The pancreas shows a good clearance after 24 h whereas the uptake in the adrenals stays relatively high (60% of the 4 h value after 48 h). A high radioligand accumulation could be measured in the tumours four hours after the injection. When the receptors were blocked by a simultaneous injection of octreotide the accumulation of radioactivity in the tumour was significantly reduced by 63%. A higher reduction could be seen in the stomach (71%), the pancreas (88%), and the adrenals (68%). Upon blocking the accumulation in the kidneys was increased by a factor of 2.5.
In all non-tumour and non-receptor-specific tissues a fast clearance of the radiopharmaceutical was observed; this even holds for the kidneys (after 48 h 15% of the activity of the 4 h value is found in this organ).
The HEK-sst2 model was used to study the pharmacokinetics at shorter time points for comparative reasons. The general picture was similar to the other tumour model. The tumour uptake was very high, doubling the value obtained using another potent sst2-selective radiopeptide, [
111 In]DTPA-TATE (IC 50 = 1.3 nM) at 4 h p.i. [31] . Blocking was performed by coinjection of 100 µg [DOTA,Tyr 3 ,Thr 8 ]octreotide (DOTATATE) and was more efficient than the blocking with 50 µg octreotide in the AR4-2J mouse model. The unspecific level was lowered to 14.7% in the tumour, 6.3% in the pancreas and 5.5% in the pituitary. The tumour uptake is persistent, even increasing, in the first 4 h whereas the initial high pancreas uptake is washing out relatively fast. The tumour/blood, tumour/liver and tumour/kidney ratios increased considerably during the first 4 hours and a value of 5.4 was never before observed in this or a similar tumour model using a somatostatin-based radiometallopeptide.
Coordination chemical aspects: It is of major importance to understand why the radiometal ion influences the receptor binding affinity and the tumour uptake. With regard to this we crystallised two model chelates, Figures 5 and 6 . Crystallographic data are summarised in Table 4 Table 5 shows some selected bond lengths, angles and planes of both chelates. The two structures are almost identical and close to the corresponding structure of Ga III (DOTA-D-PheNH 2 ) [13] showing the relevance of the structures to the monoamide peptide derivatives. In both structures, as in Ga 
Experimental Section
Chemicals and analysis: All chemicals were obtained from commercial sources and used without further purification. DOTA was a gift from Guerbet, France.
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CoCl2 was purchased from Isotope Products Laboratories, Burbank (CA), USA. Sephadex G-50 (Pharmacia) was used for gel chromatography. Electrospray ionisation (ESI) was carried out with a Finnigan SSQ 7000 spectrometer. Analytical and semipreparative HPLC was performed on a Hewlett Packard 1050 HPLC system with a multiwavelength detector and a flow through Berthold LB 506 C1 γ-detector. Quantitative γ-counting was performed on a COBRA 5003 γ-system well counter from Packard Instrument Company.
1 H/ 13 C NMR was performed with either a Varian VXR 400 at 400/101 MHz or a Varian Unity 500 at 500/126 MHz. Chemical shifts reported are relative to TMS. 59 Co NMR was performed on a Bruker AV400 spectrometer at 94.939 MHz; 0.1 M K3[Co(CN)6] in D2O was used as an external reference and the presence of signals was checked between +15000 and -1000 ppm.
Syntheses and labelling
[DOTA 0 ,Tyr 3 ]-octreotide (DOTATOC) and Ga III -DOTATOC were synthesised as described previously [13] . Serum stability studies [ 57 Co]DOTATOC was added to fresh human blood serum (1 µCi/mL) and incubated at 37°C in a CO2 atmosphere (5%). At defined times aliquots of 50-100 µL were taken and analysed by gel-chromatography (Sephadex G50, PBS buffer 0.01 M, pH 7.4). Lowand high-molecular fractions were collected and measured with a γ-counter. The amount of serum protein-bound radiopeptide was calculated by the count rates of both fractions [32] .
Thermodynamic stability and protonation constants
The thermodynamic stability constant of Co II (DOTA-D-PheNH2) -was estimated by competition experiments using DOTA as a competing chelator. For this purpose, solutions containing similar amounts of both ligands were used (0.01 M, 40 µL).
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CoCl2 was added in phosphate-buffer (0.01 M, pH 7.0, 20 µL). The mixture was incubated at room temperature at controlled pH. Aliquots of 15 µL were taken at different times and analysed by HPLC equipped with a Berthold γ-detector (CC 250-4 mm 120-3 C8, M&N, eluent: A = 0.1% TFA in H2O, B = CH3CN, 0-5 min 100% A, 25-35 min 30% B, 35 min 100% A). The protonation constants of DOTA and DOTA-D-Phe-NH2 were obtained by potentiometric titration in a thermostated cell at 25°C under a stream of N2 with a 0.5 M solution of tetramethylammonium hydroxide (standardised with potassium hydrogenophtalate) at an ionic strength adjusted to 0.5 M with tetramethylammonium nitrate in a Metrohm 665-Dosimat equipped with a 1 mL piston burette. Excess nitric acid was added to the ligand solutions to determine the lower protonation constants. All the solutions were prepared with deionised water (Millipore) which was previously boiled to remove the CO2. pH measurements were carried out with a Metrohm 645 digital pH-meter equipped with a Metrohm 6.0204.100 glass electrode combined with a calomel (3 M KCl) reference electrode. The glass electrode was calibrated with pH 4.0 and 7.0 buffers at 25°C. The pH meter/electrode system was calibrated by titration of a 3.2 mM TRIS solution with 0.5 M tetramethylammonium hydroxide at an ionic strength adjusted to 0.5 M with tetramethylammonium nitrate. The data were handled and calculated with the program TITFIT [33] .
Cell culture AR4-2J rat pancreatic tumour cells expressing sst2 were cultured in high glucose Dulbecco's minimal essential medium (DMEM), enriched with 4 nM glutamine, 10% FBS, amino acids, vitamins and penicillin-streptomycin from BioConcept (Allschwil, Switzerland). Cells were maintained in a humidified 5% CO2/air atmosphere at 37°C. The viability of the cells was assessed using trypan blue stain and counted under a microscope with a "Neubauer's counting chamber".
Receptor binding assays
Cells stably expressing human sst1, sst2, sst3, sst4 and sst5 were grown as described previously [12] . All culture reagents were supplied by Gibco and Life Technologies (Grand Island, NY). Cell membrane pellets were prepared and receptor autoradiography was performed on pellet sections (mounted on microscope slides), as described in detail previously [12] .
Complete displacement experiments were performed with the universal somatostatin radioligand Switzerland), using increasing concentrations of the unlabelled peptide ranging from 0.1 to 1000 nM. Somatostatin-28 was run in parallel as control using the same increasing concentrations. IC50-values (inhibitory concentration 50%) were calculated after quantification of the data using a computer-assisted image processing system. Tissue standards (autoradiographic [ 125 I]microscales, Amersham, UK) containing known amounts of isotopes, cross calibrated to tissue-equivalent ligand concentrations, were used for quantification [12] . The peptide concentration was measured by UV spectroscopy (ε280nm = 6849), according to the method of Reubi [12] , and was based on the exact knowledge of the elemental analysis of [DOTA 0 ,Tyr 3 ]-octreotide.
Internalisation and efflux studies Cells (10 6 /well) were distributed in six-well plates at 37°C, in a 5% CO2/air atmosphere during one night in culture medium (DMEM with 10% FBS). The medium was removed; the cells were washed and incubated for 1 h, with internalisation medium (DMEM with 1% FBS) under the same conditions as described above. Approximately 0.02 MBq/well of the radioligand (2.5 pmol/well) were added to the medium and the cells were incubated at 37°C, 5% CO2, with and without excess of peptide (1 µ g) to determine non-specific internalisation. At appropriate time periods, the internalisation was stopped by removing the medium and washing the cells with ice cold PBS. To remove the receptor-bound radioligand an acid wash was carried out with a 0.1 M glycine buffer pH 2.8, during 10 min, on ice. This procedure permits to distinguish between membrane-bound (acid-releasable) and internalised radioligand (acid-resistant). Finally, cells were solubilised with 1 M NaOH and incubated for 10 min at 37°C. The 7 radioactivity of the culture medium, the receptor-bound and the internalised fractions were measured in a γ-counter (Cobra II, Packard Instr., Switzerland). For externalisation experiments the AR4-2J cells (10 6 /well) were incubated with 2.5 pmol/well of radioligand. After 2 h of internalisation at 37°C, 5% CO2, the medium was removed and the cells were washed twice with cold PBS. An acid wash was performed, as described in the previous section. Three millilitres of internalisation medium were added to each well and the cells were incubated at 37°C. At different time points the external medium was collected and exchanged with 37°C fresh medium. Thereafter, the cells were treated with 1 M NaOH to extract the internalised radioligand. The radioactivity of the external medium and of the internalised radioligand fractions was quantified in a γ-counter. The recycled fraction was expressed as percentage of the totally internalised amount per 1 million cells.
Biodistribution studies in tumour-bearing animals
All animal experiments were performed in compliance with the Swiss laws on animal protection (approval no. 789). Male nude mice (IFFACREDO, France) were injected subcutaneously in the right abdomen with a cell suspension of a rat pancreatic cell tumour (AR4-2J, 5 million cells/50 µL). Six to seven days post injection the tumours were grown to a size of approximately 0.5 cm in diameter. The animals were split into four groups: three batches of four animals without pre-treatment for 4 h, 24 h, and 48 h biodistribution studies; four animals which were injected with 50 µg Octreotide ® together with the radiopharmaceutical. Both substances, the radioligand as well as Octreotide ® , were prepared in a 0.1% bovine serum albumin solution in order to prevent sticking of the substances to the syringes. For the second tumour model five-week-old female Swiss athymic nude mice were implanted subcutaneously with 10 millions of HEK-sst2 cells on one flank. After 10-12 days the mice showed solid palpable tumour masses of 150-200 mg. In order to study the biodistribution of [ 57 Co]DOTATOC, 3 µCi (120±15 kBq) of the radioligand was injected by the tail vein as a bolus into the tumourbearing mice. After the respective times the animals were sacrificed, a blood sample was taken, organs were removed, weighed, and the radioactivity was counted.
X-ray diffraction studies
The X-ray measurements of Ga Table 4 , average bond lengths, angles and planes in Table 5 . The structures were solved using Patterson methods, expanded by Fourier techniques and refined against F 2 by full-matrix least-squares methods using ShelX93 crystallographic software package [34] . Crystallographic data (excluding structure factors) for the structures of the gallium and the cobalt chelates have been deposited with the Cambridge Crystallographic Data Centre and allocated the deposition numbers CCDC 616729 & 616730, respectively. Copies of the data can be obtained free of charge on application to the director, CCDC, 12 Union Road, Cambridge CB2 1EZ, (fax: (+44) 1223-336-033, e-mail: deposit@ccdc.cam.ac.uk). 
Legends to the figures
